These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19744348)

  • 1. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.
    Yeh CT; Kuo CJ; Lai MW; Chen TC; Lin CY; Yeh TS; Lee WC
    BMC Cancer; 2009 Sep; 9():324. PubMed ID: 19744348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53.
    Shiota G; Oyama K; Udagawa A; Tanaka K; Nomi T; Kitamura A; Tsutsumi A; Noguchi N; Takano Y; Yashima K; Kishimoto Y; Suou T; Kawasaki H
    J Med Virol; 2000 Oct; 62(2):151-8. PubMed ID: 11002243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells.
    Liu Z; Dai X; Wang T; Zhang C; Zhang W; Zhang W; Zhang Q; Wu K; Liu F; Liu Y; Wu J
    Cancer Lett; 2017 Aug; 400():149-160. PubMed ID: 28455240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
    Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
    Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma.
    Sasaki A; Kamiyama T; Yokoo H; Nakanishi K; Kubota K; Haga H; Matsushita M; Ozaki M; Matsuno Y; Todo S
    Oncol Rep; 2010 Aug; 24(2):537-46. PubMed ID: 20596644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
    Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
    World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study.
    Na DC; Lee JE; Yoo JE; Oh BK; Choi GH; Park YN
    Exp Mol Pathol; 2011 Feb; 90(1):66-73. PubMed ID: 20969862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
    Chan AW; Tong JH; Chan SL; Lai PB; To KF
    Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
    Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
    Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk.
    Jing YY; Liu WT; Guo SW; Ye F; Fan QM; Yu GF; Yu DD; Gao L; Sun K; Han ZP; Li R; Yang Y; Zhao QD; Wu MC; Wang HY; Wei LX
    Oncotarget; 2015 Dec; 6(40):42952-62. PubMed ID: 26515593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues.
    Xuan SY; Xin YN; Chen H; Shi GJ; Guan HS; Li Y
    World J Gastroenterol; 2007 Mar; 13(12):1870-4. PubMed ID: 17465484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
    Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
    BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67.
    Abdou AG; Holah NS; Elazab DS; El-Gendy WG; Badr MT; Al-Sharaky DR
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):20-33. PubMed ID: 32287076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
    Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
    Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.